wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86
Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86
Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
P2860
Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f535421edefd10cde20980158067c7f307087121
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.